https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/biomarin-release-results-cln2-trial-being-carried-out-gosh/
Biomarin release results from CLN2 trial being carried out at GOSH
28 Jun 2016, 2:05 p.m.
Biomarin have released positive 48-week results from a clinical trial of cerliponase alfa treatment for CLN2 disease.
CLN2 disease is a form of Batten disease, a fatal neurodegenerative disease. It is the result of mutations in the TPP1/CLN2 gene causing deficient activity of the tripeptidyl peptidase 1 enzyme (TPP1). Cerliponase alfa treatment is a recombinant form of TPP1 and is designed to restore TPP1 enzyme activity.
In this Phase I/II trial, cerliponase alfa treatment was administered directly into the brain ventricles via intracerebroventricular infusions. At one year, the results have shown an 80 per cent reduction in the progression of the disease relating to decline in motor and language functioning, when compared to the natural progression of the disease. Furthermore, treatment was also found to reduce cortical grey matter loss.Biomarin plans to submit marketing applications and is planning to implement an early access programme to enable additional CLN2 patients to have access to this treatment.
The Great Ormond Street Hospital (GOSH) involvement in the trial was led by Novel Therapies Deputy Theme Lead, Professor Paul Gissen.
Fourth Annual NIHR GOSH BRC Image Competition - A Moment of Discovery
The Research and Innovation Communications team at GOSH and the NIHR GOSH Biomedical Research team invite you to enter our Research and Innovation Showcase: A Moment of Discovery.
New hope to prevent blindness in children with rare genetic disease
A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by Clinicians at GOSH and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH).
GOSH only hospital outside of North America to receive innovation funding award for AI
GOSH has been awarded the Amazon Web Services IMAGINE Grant: Children’s Health Innovation Award, to support artificial intelligence (AI) development and drive progress for children’s healthcare.
New clinical trial at GOSH gives hope to children with aggressive blood cancer
Researchers at GOSH and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) are collaborating on a novel approach to clinical trials to give hope to children with an aggressive type of blood cancer, T-cell acute lymphoblastic leukaemia (T-ALL)